Moreover, since CYP51A1 is MM-specifically upregulated in chronic hypoxia, the development and investigation of selective CYP51A1 inhibitors may be a promising strategy for anti-myeloma treatment. Here, CYP51A1 is linked to plasma cell myeloma.